COVID-19 Vaccine for Coronavirus

Recruiting at 205 trial locations

Age: 18 - 65

Sex: Any

Trial Phase: Phase 3

Sponsor: BioNTech SE

Disqualifiers: Recent COVID-19, Recent COVID-19 vaccine

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

Duration: 1 day

25500 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).

Who Is on the Research Team?

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Are You a Good Fit for This Trial?

This clinical trial is for healthy adults aged 50 to 64 who want to participate in a study about the COVID-19 vaccine. Participants should not have any serious health issues.

Inclusion Criteria

I am between 50 and 64 years old.

People who are healthy and, based on their medical history and a doctor's judgment, are considered suitable to join the study

Exclusion Criteria

I had COVID-19 within the last 3 months.

I have received a COVID-19 vaccine in the last 3 months or plan to during the study.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive one dose of either the COVID-19 vaccine or a placebo

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Multiple visits (in-person and virtual)

What Are the Treatments Tested in This Trial?

Interventions

• BNT162b2 Vaccine

Trial Overview

The trial is testing the effectiveness of the BNT162b2 COVID-19 vaccine compared with a placebo, which does not contain active ingredients against COVID-19.

How Is the Trial Designed?

Group I: BNT162b2 Vaccine Experimental Treatment 1 Intervention

Group II: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

BioNTech SE

Lead Sponsor

Trials

84

Recruited

120,000+

Prof. Dr. Ugur Sahin

BioNTech SE

Chief Executive Officer since 2008

MD from University of Cologne

Prof. Özlem Türeci

BioNTech SE

Chief Medical Officer since 2018

MD from Saarland University

Pfizer

Industry Sponsor

Trials

4,712

Recruited

50,980,000+

Known For

Vaccine Innovations

Top Products

Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University